133 related articles for article (PubMed ID: 15460638)
1. Getting to grips with an epidemic.
Desmond N
Nurs N Z; 2004 Aug; 10(7):2. PubMed ID: 15460638
[No Abstract] [Full Text] [Related]
2. The strategy to control New Zealand's epidemic of group B meningococcal disease.
O'Hallahan J; Lennon D; Oster P
Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S293-8. PubMed ID: 15597072
[TBL] [Abstract][Full Text] [Related]
3. Meningococcal B immunisation in New Zealand: why haven't we seen the data?
Bolland M
N Z Med J; 2008 Mar; 121(1270):107-9. PubMed ID: 18364764
[No Abstract] [Full Text] [Related]
4. Re: "a prospective study of the effectiveness of the New Zealand meningococcal B vaccine".
Lennon D; Stewart J; Crengle S
Am J Epidemiol; 2008 May; 167(9):1140-1; author reply 1141-2. PubMed ID: 18359952
[No Abstract] [Full Text] [Related]
5. The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic.
Sexton K; Lennon D; Oster P; Crengle S; Martin D; Mulholland K; Percival T; Reid S; Stewart J; O'Hallahan J
N Z Med J; 2004 Aug; 117(1200):U1015. PubMed ID: 15475985
[TBL] [Abstract][Full Text] [Related]
6. Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease.
O'Hallahan J; McNicholas A; Galloway Y; O'Leary E; Roseveare C
N Z Med J; 2009 Mar; 122(1291):48-59. PubMed ID: 19322255
[TBL] [Abstract][Full Text] [Related]
7. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
[TBL] [Abstract][Full Text] [Related]
8. New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months.
Wong S; Lennon D; Jackson C; Stewart J; Reid S; Crengle S; Tilman S; Aaberge I; O'Hallahan J; Oster P; Mulholland K; Martin D
Pediatr Infect Dis J; 2007 Apr; 26(4):345-50. PubMed ID: 17414400
[TBL] [Abstract][Full Text] [Related]
9. New Zealand's epidemic of meningococcal disease described using molecular analysis: implications for vaccine delivery.
Dyet K; Devoy A; McDowell R; Martin D
Vaccine; 2005 Mar; 23(17-18):2228-30. PubMed ID: 15755601
[TBL] [Abstract][Full Text] [Related]
10. Meningococcal disease: a review on available vaccines and vaccines in development.
Bröker M; Fantoni S
Minerva Med; 2007 Oct; 98(5):575-89. PubMed ID: 18043565
[TBL] [Abstract][Full Text] [Related]
11. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine.
Kelly C; Arnold R; Galloway Y; O'Hallahan J
Am J Epidemiol; 2007 Oct; 166(7):817-23. PubMed ID: 17615088
[TBL] [Abstract][Full Text] [Related]
12. MeNZB vaccine and epidemic control: when do you stop vaccinating?
Loring BJ; Turner N; Petousis-Harris H
Vaccine; 2008 Nov; 26(47):5899-904. PubMed ID: 18804134
[TBL] [Abstract][Full Text] [Related]
13. Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks.
Taha MK; Zarantonelli ML; Alonso JM; Naess LM; Holst J; Feiring B; Rosenqvist E
Vaccine; 2007 Mar; 25(14):2537-8. PubMed ID: 16460845
[No Abstract] [Full Text] [Related]
14. The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease.
Holst J; Feiring B; Naess LM; Norheim G; Kristiansen P; Høiby EA; Bryn K; Oster P; Costantino P; Taha MK; Alonso JM; Caugant DA; Wedege E; Aaberge IS; Rappuoli R; Rosenqvist E
Vaccine; 2005 Mar; 23(17-18):2202-5. PubMed ID: 15755595
[TBL] [Abstract][Full Text] [Related]
15. Prevention of group B meningococcal disease by vaccination: a difficult task.
Thomas M
N Z Med J; 2004 Aug; 117(1200):U1016. PubMed ID: 15475986
[TBL] [Abstract][Full Text] [Related]
16. Serogroup B meningococcal disease during Hajj: preparing for the worst scenario.
Khalil MK; Borrow R
Travel Med Infect Dis; 2009 Jul; 7(4):231-4. PubMed ID: 19717106
[TBL] [Abstract][Full Text] [Related]
17. Epidemic meningococcal disease in New Zealand: epidemiology and potential for prevention by vaccine.
Bremner C; Lennon D; Martin D; Baker M; Rümke H
N Z Med J; 1999 Jul; 112(1091):257-9. PubMed ID: 10448985
[No Abstract] [Full Text] [Related]
18. Pediatric Invasive Meningococcal Disease, Auckland, New Zealand (Aotearoa), 2004-2020.
Burton C; Best E; Broom M; Heffernan H; Briggs S; Webb R
Emerg Infect Dis; 2023 Apr; 29(4):686-695. PubMed ID: 36957984
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the post-licensure effectiveness of a group B meningococcal vaccine in New Zealand: a multi-faceted strategy.
Ameratunga S; Macmillan A; Stewart J; Scott D; Mulholland K; Crengle S;
Vaccine; 2005 Mar; 23(17-18):2231-4. PubMed ID: 15755602
[TBL] [Abstract][Full Text] [Related]
20. The risk of simple febrile seizures after immunisation with a new group B meningococcal vaccine, New Zealand.
Stehr-Green P; Radke S; Kieft C; Galloway Y; McNicholas A; Reid S
Vaccine; 2008 Feb; 26(6):739-42. PubMed ID: 18187240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
